Accessibility Menu
Sarepta Therapeutics logo

Sarepta Therapeutics(NASDAQ) SRPT

Current Price$16.03
Market Cap$1.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-58%
5 Year-77%
1 Year+22%
1 Month-8%
Sarepta Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 16.212026-07-21
Sarepta Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.74%USD 17.962026-07-14
1 month-7.53%USD 17.532026-06-18
3 month-21.46%USD 20.642026-04-22
Year to date-24.67%USD 21.522025-12-31
1 year+21.7%USD 13.322025-07-21
3 year-84.69%USD 105.872023-07-21
5 year-76.54%USD 69.112021-07-22
Since inception-58.44%USD 39.001997-06-04

Sarepta Therapeutics Financials at a Glance

Market Cap

$1.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.18B

Net Income (TTM)

$65.06M

EPS (TTM)

-$0.96

P/E Ratio

-16.81

Dividend

$0.00

Beta (Volatility)

1.07 (Average)

Price

$16.03

Volume

71,041

Open

$16.22

Previous Close

$16.21

Daily Range

$15.91 - $16.36

52-Week Range

$10.42 - $25.32

Estimated Earnings Date

Aug 5, 2026

SRPT News

Doctor and patient in a hospital room.

2 Beaten-Down Stocks That Could Sink Even More in 2026

Prosper Junior BakinyJan 21, 2026
Doctor with patient talking

Is This Stock a Buy After Soaring by 20% in 1 Day?

Prosper Junior BakinyJul 24, 2025
Person sitting at a desk looking at two monitors

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

Prosper Junior BakinyMar 23, 2025
doctor and businessman working on digital tablet in the office

After a Big Win, Is Sarepta Therapeutics Stock a Buy?

Alex CarchidiJul 6, 2024
A doctor looking at a tablet with another person.

Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?

David Jagielski, CPAJul 4, 2024
Physician giving a high five to a young patient

1 Soaring Growth Stock to Buy and Hold for 10 Years

Prosper Junior BakinyJul 3, 2024
Physician giving a high five to a young patient

1 Top Growth Stock to Buy and Hold for 10 Years

Prosper Junior BakinyMay 1, 2024
investor ponders phone and laptop stock charts

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

Alex CarchidiMar 13, 2024
Page 1

SRPT: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sarepta Therapeutics

Sarepta makes medicines for rare genetic diseases. These products help children with muscle-wasting conditions. The company uses advanced technology to fix genetic errors.

What is on the Pharmacy Shelf?

  • ELEVIDYS: Gene therapy that delivers a functional version of a critical protein to patients with Duchenne muscular dystrophy.
  • EXONDYS 51: Injection for patients with a specific genetic mutation that allows for the skipping of certain genetic sections to improve muscle health.
  • VYONDYS 53: Treatment targeting a subset of patients who require exon skipping for a specific part of the dystrophin gene.
  • AMONDYS 45: Medicine designed for patients with a confirmed mutation amenable to skipping exon 45 to restore protein production.

Alliances and Pipelines

  • Partnered with Arrowhead Pharmaceuticals in November 2024 to develop new medicines using RNA interference technology, which blocks the production of disease-causing proteins.
  • Collaborated with F. Hoffman-La Roche Ltd to commercialize its lead gene therapy in countries outside of the United States.
  • Acquired Myonexus Therapeutics in April 2019 to expand its portfolio into gene therapies for limb-girdle muscular dystrophy.
  • Contracted with Catalent in November 2022 to secure specialized manufacturing space for the production of gene therapy products.

A Specialized Approach to Biotech

Sarepta maintains its position in genetic medicine through proprietary platforms that target rare diseases at the molecular level. Its distribution model uses a limited network of specialty pharmacies and hospital clinics to manage complex patient needs and treatment schedules.

Tracking the Vital Signs

  • Net revenue reached $1.86 billion for the full year 2025, up from $1.79 billion in 2024.
  • Revenue was $442.9 million in Q4 2025, down 32.7% from Q4 2024.
  • Net income fell to -$282.8 million in Q4 2025, down 277.8% from Q4 2024.
  • Free cash flow rose to $125.4 million in Q4 2025, up 132.3% from Q4 2024.

The Path Forward

Sarepta has transitioned from a research firm into a commercial provider of genetic medicines for rare disorders. Its long-term strategy focuses on diversifying its therapeutic pipeline and stabilizing its complex manufacturing and partnership networks.

AI Generated • Apr 27, 2026

Industry

Biotechnology

Sector

Health Care

Employees

835

CEO

Douglas S. Ingram

Website

www.sarepta.com

Headquarters

Cambridge, MA 02142, US

SRPT Financials

Key Financial Metrics (TTM)

Gross Margin

62.39%

Operating Margin

-1.88%

Net Income Margin

2.98%

Return on Equity

4.89%

Return on Capital

-30.17%

Return on Assets

2.05%

Earnings Yield

-5.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

105.58M

Volume

71.04K

Avg. Volume

3.35M

Financials (TTM)

Gross Profit

$1.36B

Operating Income

-$40.96M

EBITDA

$124.95M

Operating Cash Flow

$175.28M

Capital Expenditure

-$69.14M

Free Cash Flow

$106.14M

Cash & ST Invst.

$653.19M

Total Debt

$1.04B

Sarepta Therapeutics Performance Analysis

Sarepta Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 933,013,00032.9%
20232023-12-31USD 1,243,336,00033.3%
20242024-12-31USD 1,901,979,00053.0%
20252025-12-31USD 2,198,237,00015.6%
Sarepta Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-18.0%
Q32025-09-30-34.6%
Q42025-12-3110.9%
Q12026-03-3165.0%
Sarepta Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -8.0355.9%
20232023-12-31USD -5.80-27.8%
20242024-12-31USD 2.34N/A
20252025-12-31USD -7.13N/A
Sarepta Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30141.1%
Q32025-09-30-195.2%
Q42025-12-31-118.3%
Q12026-03-31173.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$730.80M

-1.9%

Gross Profit

$611.44M

+0.7%

Gross Margin

83.67%

N/A

Market Cap

$1.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.05M

N/A

Employees

835

N/A

Net Income

$330.96M

+174.0%

EBITDA

$375.48M

+201.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$653.19M

+24.9%

Total Debt

$1.04B

-22.9%

Accounts Receivable

$547.91M

-24.4%

Inventory

$1.00B

+6.3%

Long Term Debt

$1.04B

-22.9%

Short Term Debt

$0.00

N/A

Return on Assets

2.05%

N/A

Return on Invested Capital

-1.53%

N/A

Free Cash Flow

-$205.76M

+67.3%

Operating Cash Flow

-$202.68M

+65.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MLYSMineralys Therapeutics, Inc.
$27.27-0.91%
RXRXRecursion Pharmaceuticals, Inc.
$3.00-2.59%
AGIOAgios Pharmaceuticals, Inc.
$36.09-3.41%
ETNB89bio, Inc.
$14.84+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.08+0.05%
SMCISuper Micro Computer
$31.05+0.22%
RIGTransocean
$5.30+0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.66+0.01%

Questions About SRPT

What is the current price of Sarepta Therapeutics?

Sarepta Therapeutics is trading at $16.03 per share.

What is the 52-week range for Sarepta Therapeutics?

Over the past 52 weeks, Sarepta Therapeutics has traded between $10.42 and $25.32.

How much debt does Sarepta Therapeutics have?

As of the most recent reporting period, Sarepta Therapeutics reported total debt of $1.04B.

How much cash does Sarepta Therapeutics have on hand?

Sarepta Therapeutics reported $464.45M in cash and cash equivalents in its most recent financial results.

What is Sarepta Therapeutics’s dividend yield?

Sarepta Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services